Combination of irinotecan hydrochloride (CPT-11) and Cisplatin as a new regimen for patients with advanced ovarian cancer

Acta Obstetrica et Gynaecologica Japonica

Volumn 48, Issue 9, 1996, Pages 827-834

  Sugiyama, Toru ^a   Nishida, Takashi ^a   Kataoka, Akio ^a   Imaishi, Kiyohisa ^a   Komai, Kan ^a   Ushijima, Kimio ^a   Hasuo, Yasuyuki ^a   Ookura, Naofumi ^a   Yakushiji, Michiaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; CPT 11; Ovarian cancer

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; OVARY CANCER; RECURRENT CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CISPLATIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OVARIAN NEOPLASMS;

EID: 0029820351     PISSN: 03009165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1891 ; 18 : 222-232
2. Gruppo Interregionale Cooperative Oncologico Ginecologia. Randomized comparison of cisplatin with cyclophosphamid/doxorubicin in advanced ovarian cancer. Lancet 1987 ; 2 : 353 -359
3. Ozols RF. Ovarian cancer. Part II. Treatment. Curr Probl Cancer 1992 ; 16 : 61-126
4. Kawato Y, Aonuma M, Hirota Y, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res 1991 ; 51 : 4187-4191
5. Negoro S, Fukuoka M, Nütani H, Taguchi T. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991 ; 10 : 241
6. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi, Y, Negoro S, Masuda N, Nakajima S, Taguchi T (for CPT-11 Lung Cancer Study Group). A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992 ; 10 : 16-20
7. Shimada Y, Yoshino M, Wakui A, Nakano I, Futatsuki K, Sakala Y, Kambe M, Taguchi T, Ogawa N (the CPT-11 Gastrointestinal Cancer Study Group). Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993 ; 11 : 909-913
8. Sugiyama T, Yakushiji M, Noda K, Takeuchi S (The CPT-11 Study Group on the Gynecologic Malignancy in Japan). Phase 1 study of irinotecan (CPT-11) in combined with cisplatin in cervical and ovarian carcinoma. Proc the firth conference on DNA topoisomerases in therapy. 1994 ; 47
9. Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma. Retreatment utilizing combination chemotherapy including cisdiaminodichloroplatinum in patients previously responding to this agent. Gynecol Oncol 1985 ; 21 : 167-176
10. Zanaboni F, Scarfone G, Presti M, Maggi R, Borello C, Bolis G. Salvage chemotherapy for ovarian cancer recurrence: Weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 1991 ; 43 : 24-28
11. Reed E. Jacob J, Ozols RF, Young RC, Allegra C. 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovraian carcinoma. Gynecol Oncol 1992 ; 46 : 326-329
12. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 ; 9 : 389 -393
13. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term fullow up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992 ; 10 : 1748-1753
14. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993 ; 71 : 559-564
15. Tsuruo T, Matsuzaki T, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumours in vitro and vivo. Cancer Chemother Pharmacol 1988 ; 21 : 71-74
16. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y. Effect of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992 ; 30 : 604-610
17. Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro S, Mitsui K, Takifuji N, Morino H, Fukuoka M. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xeno-grafts. Jpn J Cancer Res 1993 ; 84 : 203-207